American Journal of Obstetrics & Gynecology
Volume 201, Issue 1 , Pages 17.e1-17.e8 , July 2009

Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping

  • Sophia Brismar, MD

      Affiliations

    • Division of Obstetrics and Gynecology, Department for Clinical Science, Intervention and Technology, Karolinska University Hospital–Huddinge, Karolinska Institute, Stockholm, Sweden
    • ,
  • Bo Johansson, PhD

      Affiliations

    • Division of Clinical Virology, Department of Laboratory Medicine, Karolinska University Hospital–Huddinge, Karolinska Institute, Stockholm, Sweden
    • ,
  • Malin Borjesson, MD

      Affiliations

    • Division of Obstetrics and Gynecology, Department for Clinical Science, Intervention and Technology, Karolinska University Hospital–Huddinge, Karolinska Institute, Stockholm, Sweden
    • ,
  • Marc Arbyn, PhD

      Affiliations

    • Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    • ,
  • Sonia Andersson, MD, PhD

      Affiliations

    • Division of Obstetrics and Gynecology, Department for Clinical Science, Intervention and Technology, Karolinska University Hospital–Huddinge, Karolinska Institute, Stockholm, Sweden
    • Corresponding Author InformationReprints: Sonia Andersson, MD, PhD, Department for Clinical Science, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska University Hospital–Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden

Received 29 July 2008 ,Revised 31 October 2008 ,Accepted 12 January 2009.

References 

  1. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999;91:252–258
  2. Bollen LJ, Tjong AHSP, van der Velden J, et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol. 1999;72:199–201
  3. Nuovo J, Melnikow J, Willan AR, Chan BKS. Treatment outcomes for squamous intraepithelial lesions. Int J Gynecol Obstet. 2000;68:25–33
  4. Almog B, Gamzu R, Kuperminc MJ, et al. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2003;88:345–350
  5. Alonso I, Torne A, Puig-Tintore LM, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol. 2006;103:631–636
  6. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99:S7–S11
  7. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(suppl 3):S78–S89
  8. Jordan J, Martin-Hirsch P, Arbyn M, et al. Chapter 6: Management of abnormal cervical cytology (European guidelines for quality assurance in cervical cancer screening). Luxembourg: Office for Official Publications of the European Communities. 2008;191–232
  9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  10. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–632
  11. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204
  12. Zur Hausen H, Arbyn M, Bosch F, et al. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1–636
  13. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527
  14. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272–1278
  15. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–428
  16. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24:S16–S22
  17. Song SH, Lee JK, Oh MJ, et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol. 2006;101:418–422
  18. Verguts J, Bronselaer B, Donders G, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG. 2006;113:1303–1307
  19. Strander B, Ryd W, Wallin KL, et al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?. Eur J Cancer. 2007;43:1849–1855
  20. Mints M, Gaberi V, Andersson S. Miniconization procedure with C-LETZ conization electrode for treatment of cervical intraepithelial neoplasia: a Swedish study. Acta Obstet Gynecol Scand. 2006;85:218–223
  21. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology. 2007;18:133–139
  22. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301–328
  23. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–2119
  24. Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the Hybrid Capture II Test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol. 2005;43:3260–3266
  25. Monsonego J, Pollini G, Evrard MJ, et al. Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis. 2008;35:521–527
  26. Woo YL, Damay I, Stanley M, Crawford R, Sterling J. The use of HPV linear array assay for multiple HPV typing on archival frozen tissue and DNA specimens. J Virol Methods. 2007;142:226–230
  27. Costa S, Simone PD, Venturoli S, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol. 2003;90:358–365
  28. Fen J, Yoshinouchi M, Nakamura K, et al. Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep. 2004;12:375–379
  29. Chao A, Lin CT, Hsueh S, et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol. 2004;190:1046–1051
  30. Kreimer AR, Guido RS, Solomon D, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006;15:908–914
  31. Elfgren K, Jacobs M, Walboomers JMM, Meijer CJLM, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol. 2002;100:965–971
  32. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?. Gynecol Oncol. 2000;79:294–299
  33. Munger K. The role of human papillomaviruses in human cancers. Front Biosci. 2002;7:d641–d649
  34. Longworth MS, Laimins LA, Doorbar J, et al. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68:362–372
  35. Doorbar J, Coupe VM, Berkhof J, Verheijen RH, Meijer CJ. The papillomavirus life cycle. J Clin Virol. 2005;32(suppl 1):S7–S15
  36. Doorbar J, Coupe VM, Berkhof J, Verheijen RH, Meijer CJ. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110:525–541
  37. Guo Z, Wu F, Asplund A, et al. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod Pathol. 2001;14:54–61
  38. Baker JJ. Conventional and liquid-based cervicovaginal cytology: a comparison study with clinical and histologic follow-up. Diagn Cytopathol. 2002;27:185–188
  39. Zielinski GD, Rozendaal L, Voorhorst FJ, et al. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2003;91:67–73
  40. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ. 2005;331:1183–1185
  41. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118:2048–2055
  42. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ. 2007;335:1077

 This study was supported by the Directorate of SANCO, Luxembourg, Grand-Duchy of Luxembourg; European Commission, through the European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines, IARC, Lyons, France; Grants from the Swedish Cancer Foundation, the Swedish Research Council, and the Medical Research Council, as well as the Cancer Society in Stockholm, Sweden; the Stockholm County Council, Sweden; the Swedish Labour Market Insurance; the Federal Service for Science, Culture and Technology, Brussels, Belgium (DWTC/SSTC); and the Institute for the Promotion of Innovation by Science and Technology (IWT) in Flanders, project no. 060081.

 Cite this article as: Brismar S, Johansson B, Borjesson M, et al. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009;201:17.e1-8.

PII: S0002-9378(09)00011-8

doi: 10.1016/j.ajog.2009.01.005

American Journal of Obstetrics & Gynecology
Volume 201, Issue 1 , Pages 17.e1-17.e8 , July 2009

Article Tools

* Image Usage & Resolution